Medicare Enrolled
Dr. Diraj Karnani, M. D.
Rheumatology · Apple Valley, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Karnani from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Karnani?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Karnani
Dr. Diraj Karnani is a rheumatology specialist in Apple Valley, CA, with 12 years of NPI registration. Based on federal Medicare data, Dr. Karnani performed 24,915 Medicare services across 1,205 unique beneficiaries.
Between the years covered by Open Payments, Dr. Karnani received a total of $8,118 from 46 pharmaceutical and/or device companies across 354 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Karnani is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 12 years in practice
▲ Top 16% volume in CA
$8,118 industry payments
Medicare Practice Summary
Medicare Utilization ↗24,915
Medicare services
Top 16% in CA for rheumatology
1,205
Unique beneficiaries
$27
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,076 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
7,600 | $10 | $42 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
5,765 | $26 | $119 |
| Infliximab-abda biosimilar injection, 10 mg This code represents the administration of a 10 mg dose of infliximab-abda, a biosimilar medication. It covers the injection of this specific pharmaceutical product. |
4,271 | $31 | $137 |
| Denosumab injection (Prolia/Xgeva) | 4,260 | $18 | $70 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,363 | $99 | $239 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
353 | $108 | $472 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
253 | $62 | $234 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
251 | $23 | $101 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
157 | $74 | $205 |
| Complete ultrasound scan of joint An ultrasound exam that uses sound waves to create detailed images of a joint. This procedure allows for the visualization of the joint's internal structures. |
136 | $42 | $250 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
124 | $129 | $305 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
93 | $6 | $33 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
74 | $48 | $191 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
59 | $13 | $55 |
| Injection, methylprednisolone acetate, 40 mg | 59 | $6 | $202 |
| Methylprednisolone acetate injection, 20 mg A 20 mg injection of methylprednisolone acetate, a corticosteroid medication. This code specifies the drug and dosage administered. |
46 | $5 | $198 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
22 | $49 | $233 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
18 | $147 | $257 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
11 | $141 | $248 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
55.1% high complexity
38.1% medium
6.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,118
Total received (2018-2024)
Avg $1,160/year across 7 years
Top 32% in CA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
354
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,330 (78.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,677 (20.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$112 (1.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,226
2023
$1,422
2022
$1,100
2021
$2,071
2020
$639
2019
$1,333
2018
$327
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$389
Amgen Inc.
$197
Janssen Biotech, Inc.
$60
Lundbeck LLC
$60
Genentech USA, Inc.
$56
GlaxoSmithKline, LLC.
$55
UCB, Inc.
$54
PFIZER INC.
$52
SK Life Science, Inc.
$41
Lilly USA, LLC
$38
Novartis Pharmaceuticals Corporation
$38
Vanda Pharmaceuticals Inc.
$26
Fresenius Kabi USA, LLC
$24
CATALYST PHARMACEUTICALS, INC.
$24
Aurinia Pharma U.S., Inc.
$22
Radius Health, Inc.
$20
SCILEX PHARMACEUTICALS INC.
$19
Sandoz Inc.
$18
LivaNova USA, Inc.
$18
Kyowa Kirin, Inc.
$13
Top 3 companies account for 52.7% of 2024 payments
All-time payments by company (2018-2024) ›
UCB, Inc.
$1,854
Amgen Inc.
$1,153
ABBVIE INC.
$1,120
Novartis Pharmaceuticals Corporation
$521
AbbVie Inc.
$438
AbbVie, Inc.
$253
GlaxoSmithKline, LLC.
$235
PFIZER INC.
$216
Horizon Therapeutics plc
$196
Genentech USA, Inc.
$180
Lilly USA, LLC
$164
E.R. Squibb & Sons, L.L.C.
$135
Teva Pharmaceuticals USA, Inc.
$131
AstraZeneca Pharmaceuticals LP
$125
Bayer HealthCare Pharmaceuticals Inc.
$108
Biogen, Inc.
$106
SK Life Science, Inc.
$100
Janssen Biotech, Inc.
$98
EMD Serono, Inc.
$93
Lundbeck LLC
$75
GENZYME CORPORATION
$68
Mallinckrodt Hospital Products Inc.
$62
LivaNova USA, Inc.
$61
Celgene Corporation
$61
Mallinckrodt Enterprises LLC
$50
Harmony Biosciences LLC
$49
Boehringer Ingelheim Pharmaceuticals, Inc.
$43
Biohaven Pharmaceutical Holding Company Ltd.
$38
Kyowa Kirin, Inc.
$36
Radius Health, Inc.
$35
Mallinckrodt LLC
$30
Vanda Pharmaceuticals Inc.
$26
Fresenius Kabi USA, LLC
$24
CATALYST PHARMACEUTICALS, INC.
$24
Aurinia Pharma U.S., Inc.
$22
Acorda Therapeutics, Inc
$20
Sobi, Inc
$19
SCILEX PHARMACEUTICALS INC.
$19
Avanir Pharmaceuticals, Inc.
$19
Sandoz Inc.
$18
Bioventus LLC
$18
Otsuka America Pharmaceutical, Inc.
$17
MITSUBISHI TANABE PHARMA AMERICA, INC.
$15
Upsher-Smith Laboratories LLC
$14
Horizon Pharma plc
$14
Sunovion Pharmaceuticals Inc.
$12
Top 3 companies account for 50.9% of all-time payments
Associated products mentioned in payments ›
ACTHAR · ADUHELM · AUSTEDO · Actemra · Aimovig · Austedo XR · BENLYSTA · BOTOX · COSENTYX · CYLTEZO · Cimzia · Crysvita · Durolane · EVENITY · Enbrel · Enspryng · FYCOMPA · HUMIRA · HYRIMOZ · Humira · IDACIO · INBRIJA · KEVZARA · KRYSTEXXA · KYNMOBI · Kerendia · Kineret · LUPKYNIS · LYRICA · Mavenclad · NUEDEXTA · NURTEC ODT · Nourianz · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · Ocrevus · Otezla · PONVORY · Prolia · QUDEXY XR Topiramate Extended Release Capsules · QULIPTA · RADICAVA · RAYOS · REXULTI · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rinvoq · SAPHNELO · SIMPONI ARIA · SKYRIZI · TALTZ · TAVNEOS · TREMFYA · TYSABRI · Tymlos · UBRELVY · UPLIZNA · VNS THERAPY SENTIVA MODEL 1000 GENERATOR · VNS Therapy · VYEPTI · Wakix · XELJANZ · ZTLido · Zilbrysq
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (78%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Rheumatologists within 10 mi
5
Per 100K population
0.2
County median income
$82,184
Nearest hospital
PROVIDENCE ST MARY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Karnani is a mixed practice specialist, with above-average Medicare volume (top 16% in CA), with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Karnani experienced with golimumab infusion (simponi aria)?
Based on Medicare claims data, Dr. Karnani performed 7,600 golimumab infusion (simponi aria) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Karnani receive payments from pharmaceutical companies?
Yes. Dr. Karnani received a total of $8,118 from 46 companies across 354 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Karnani's costs compare to other rheumatologists in Apple Valley?
Dr. Karnani's average Medicare payment per service is $27. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Karnani) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Apple Valley
Browse rheumatologists in Apple Valley ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in CA
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in CA
Which CA rheumatologists receive the most from drug and device companies.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology